Cited by 6,712Pancreatic and Hepatic Oncology ResearchCancer Treatment and PharmacologyPancreatitis Pathology and Treatment

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Open access

Von Hoff, Daniel D., Ervin, Thomas, Arena, Francis P., Chiorean, E. Gabriela, Infante, Jeffrey, Moore, Malcolm, Seay, Thomas, Tjulandin, Sergei A., Ma, Wen Wee, Saleh, Mansoor N., Harris, Marion, Reni, Michele, Dowden, Scot, Laheru, Daniel, Bahary, Nathan, Ramanathan, Ramesh K., Tabernero, Josep, Hidalgo, Manuel, Goldstein, David, Van Cutsem, Eric, Wei, Xinyu, Iglesias, Jose, Renschler, Markus F.·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1304369PMC PMC4631139

Open this paper in CoChat — free account

Abstract

BACKGROUND: In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted a phase 3 study of the efficacy and safety of the combination versus gemcitabine monotherapy in patients with metastatic pancreatic cancer. METHODS: We randomly assigned patients with a Karnofsky performance-status score of 70 or more (on a scale from 0 to 100, with higher scores indicating better performance status) to nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks or gemcitabine monotherapy (1000 mg per square meter) weekly for 7 of 8 weeks (cycle 1) and then on days 1, 8, and 15 every 4 weeks (cycle 2 and subsequent cycles). Patients received the study treatment until disease progression. The primary end point was overall survival; secondary end points were progression-free survival and overall response rate. RESULTS: A total of 861 patients were randomly assigned to nab-paclitaxel plus gemcitabine (431 patients) or gemcitabine (430). The median overall survival was 8.5 months in the nab-paclitaxel-gemcitabine group as compared with 6.7 months in the gemcitabine group (hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). The survival rate was 35% in the nab-paclitaxel-gemcitabine group versus 22% in the gemcitabine group at 1 year, and 9% versus 4% at 2 years. The median progression-free survival was 5.5 months in the nab-paclitaxel-gemcitabine group, as compared with 3.7 months in the gemcitabine group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.58 to 0.82; P<0.001); the response rate according to independent review was 23% versus 7% in the two groups (P<0.001). The most common adverse events of grade 3 or higher were neutropenia (38% in the nab-paclitaxel-gemcitabine group vs. 27% in the gemcitabine group), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). Febrile neutropenia occurred in 3% versus 1% of the patients in the two groups. In the nab-paclitaxel-gemcitabine group, neuropathy of grade 3 or higher improved to grade 1 or lower in a median of 29 days. CONCLUSIONS: In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1304369

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Self-citation
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
Gradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159
Self-citation
Gemcitabine Plus nab -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Hoff, D. D. V., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N. P., Trieu, V. N., Iglesias, J. L. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,040
Self-citation
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D. B., Steward, W. P., Harper, P., Dunn, J., Smith, C. T., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 822
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study
Chauffert, B., Mornex, F., Bonnetain, F., Rougier, P. R., Mariette, C., Bouché, O., Bosset, J.-F., Aparicio, T., Mineur, L., Azzedine, A., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn281 · Cited by 696
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 643

Show all 23 references

Sorted by citations

Items 401–500 of 1,022

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer
Initiative, A. P. C. G., Harris, N. L. E., Vennin, C., Conway, J. R. W., Vine, K. L., Pinese, M., Cowley, M. J., Shearer, R. F., Lucas, M. C., Herrmann, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.63 · Cited by 121
Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting
Pothuraju, R., Rachagani, S., Junker, W. M., Chaudhary, S., Saraswathi, V., Kaur, S., & Batra, S. K. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0963-4 · Cited by 119
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer
Seppälä, T. T., Zimmerman, J. W., Sereni, E., Plenker, D., Suri, R., Rozich, N., Blair, A. B., Thomas, D. L., Teinor, J. A., Javed, A. A., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004200 · Cited by 122
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
Ketogenic diet and chemotherapy combine to disrupt pancreatic cancer metabolism and growth
Yang, L., TeSlaa, T. A., Ng, S., Nofal, M., Wang, L., Lan, T., Zeng, X., Cowan, A. J., McBride, M. J., Lu, W., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.008 · Cited by 119
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
Koltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 119
Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review
de Geus, S. W. L., Eskander, M. F., Kasumova, G. G., Ng, S. C., Kent, T. S., Mancias, J. D., Callery, M. P., Mahadevan, A., & Tseng, J. F. (2017) · Cancer · doi:10.1002/cncr.30856 · Cited by 118
Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients
Kluger, M. D., Epelboym, I., Schrope, B., Mahendraraj, K., Hecht, E. M., Susman, J., Weintraub, J. L., & Chabot, J. A. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5034-x · Cited by 118
Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells
Zarei, M., Lal, S., Parker, S. J., Nevler, A., Gohar, A. V., Dukleska, K., Mambelli-Lisboa, N. C., Moffat, C., Blanco, F. F., Chand, S. N., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0015 · Cited by 119
The Wnt signaling pathway: a potential therapeutic target against cancer
Ghosh, N., Hossain, U., Mandal, A., & Sil, P. C. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14027 · Cited by 118
Advances in the management of pancreatic cancer
Chiaro, M. D., Sugawara, T., Karam, S. D., & Messersmith, W. A. (2023) · BMJ · doi:10.1136/bmj-2022-073995 · Cited by 118
Cholesterol‐loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice
Valenza, M., Chen, J. Y., Di Paolo, E., Ruozi, B., Belletti, D., Ferrari Bardile, C., Leoni, V., Caccia, C., Brilli, E., Di Donato, S., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505413 · Cited by 112
Multiple Layer‐by‐Layer Lipid‐Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models
Li, F., Zhao, X. L., Wang, H., Zhao, R., Ji, T., Ren, H., Anderson, G. J., Nie, G., & Hao, J. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201401583 · Cited by 117
The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms
Chand, S. N., O’Hayer, K., Blanco, F. F., Winter, J. M., & Brody, J. R. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14951 · Cited by 117
Preoperative predictors for early recurrence of resectable pancreatic cancer
Nishio, K., Kimura, K., Amano, R., Yamazoe, S., Ohrira, G., Nakata, B., Hirakawa, K., & Ohira, M. (2017) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-1078-z · Cited by 117
Sequentially Triggered Nanoparticles with Tumor Penetration and Intelligent Drug Release for Pancreatic Cancer Therapy
He, X., Chen, X., Liu, L., Zhang, Y., Lü, Y., Zhang, Y., Chen, Q., Ruan, C., Guo, Q., Li, C., et al. (2018) · Advanced Science · doi:10.1002/advs.201701070 · Cited by 117
Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
Rech, A. J., Dada, H., Kotzin, J. J., Henao‐Mejia, J., Minn, A. J., Victor, C. T.-S., & Vonderheide, R. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3821 · Cited by 117
Quercetin-Modified Metal–Organic Frameworks for Dual Sensitization of Radiotherapy in Tumor Tissues by Inhibiting the Carbonic Anhydrase IX
Ma, T., Liu, Y., Wu, Q., Luo, L., Cui, Y., Wang, X., Chen, X., Tan, L., & Meng, X. (2019) · ACS Nano · doi:10.1021/acsnano.8b09221 · Cited by 117
CAR T‐cell therapy for pancreatic cancer
DeSelm, C. J., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24627 · Cited by 116
Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer
Court, C. M., Ankeny, J. S., Sho, S., Winograd, P., Hou, S., Song, M., Wainberg, Z. A., Girgis, M. D., Graeber, T. G., Agopian, V. G., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6290-8 · Cited by 116
Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels
Seifert, A. M., Reiche, C., Heiduk, M., Tannert, A., Meinecke, A.-C., Baier, S., von Renesse, J., Kahlert, C., Distler, M., Welsch, T., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1186-7 · Cited by 116
Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer
Yuan, H., Guo, H., Luan, X., He, M., Li, F., Burnett, J., Truchan, N. A., & Sun, D. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01221 · Cited by 116
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
Hecht, J. R., Lonardi, S., Bendell, J. C., Sim, H., Macarulla, T. M., Lopez, C. D., Cutsem, E. V., Martín, A. J. M., Park, J. O., Greil, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02232 · Cited by 116
Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)
Chen, I. M., Johansen, J. S., Theile, S., Hjaltelin, J. X., Novitski, S. I., Brunak, S., Hasselby, J. P., Willemoe, G. L., Lorentzen, T., Madsen, K. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02511 · Cited by 118
Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress
Jiang, X., Ma, Y., Wang, T., Zhou, H., Wang, K., Shi, W., Qin, L., Guan, J., Li, L., Long, B., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.025 · Cited by 116
Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF
Blasco, M. T., Navas, C., Martín-Serrano, G., Graña-Castro, O., Lechuga, C. G., Martín-Díaz, L., Djurec, M., Li, J., Morales-Cacho, L., Esteban-Burgos, L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.002 · Cited by 115
Self-citation
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
Wang, J. P., Wu, C., Yeh, Y.-C., Shyr, Y., Wu, Y.-Y., Kuo, C., Hung, Y., Chen, M., Lee, W., Luo, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4216 · Cited by 115
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O'Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 115
Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 115
State of the art and future directions of pancreatic ductal adenocarcinoma therapy
Neuzillet, C., Tijeras‐Raballand, A., Bourget, P., Cros, J. F., Couvelard, A., Sauvanet, A., Vullierme, M., Tournigand, C., & Hammel, P. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.08.006 · Cited by 114
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis
Satoi, S., Fujii, T., Yanagimoto, H., Motoi, F., Kurata, M., Takahara, N., Yamada, S., Yamamoto, T., Mizuma, M., Honda, G., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001705 · Cited by 114
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
Giovannetti, E., van der Borden, C. L., Frampton, A. E., Ali, A., Firuzi, O., & Peters, G. J. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.006 · Cited by 114
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine In Vitro and In Vivo to Induce Pancreatic Ductal Adenocarcinoma Regression
Wallez, Y., Dunlop, C. R., Johnson, T. I., Koh, S., Fornari, C., Yates, J. W. T., Fernández, S. B. D. Q., Lau, A., Richards, F. M., & Jodrell, D. I. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0010 · Cited by 114
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial
Hammel, P. R., Portales, F., Mineur, L., Metges, J., André, T., de la Fouchardière, C., Louvet, C., Hajbi, F. E., Faroux, R., Guimbaud, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.020 · Cited by 114
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
Crocenzi, T. S., Cottam, B., Newell, P., Wolf, R., Hansen, P., Hammill, C. W., Solhjem, M. C., To, Y.-Y., Greathouse, A., Tormoen, G. W., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0149-6 · Cited by 114
Cancer targeted therapeutics: From molecules to drug delivery vehicles
Liu, D., & Auguste, D. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.041 · Cited by 113
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma
Reni, M., Zanon, S. M., Balzano, G., Nobile, S., Pircher, C. C., Chiaravalli, M., Passoni, P., Arcidiacono, P. G., Nicoletti, R., Crippa, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx495 · Cited by 113
Self-citation
Drug Delivery in Cancer Therapy, Quo Vadis?
Lu, Z., & Qiao, P. L. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00037 · Cited by 113
Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5
Ando, Y., Ohuchida, K., Otsubo, Y., Kibe, S., Takesue, S., Abe, T., Iwamoto, C., Shindo, K., Moriyama, T., Nakata, K., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228015 · Cited by 113
Nanomedicines - Tiny particles and big challenges
Marques, M. R. C., Choo, Q., Ashtikar, M., Rocha, T. C., Bremer‐Hoffmann, S., & Wacker, M. G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.003 · Cited by 112
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Davis, S. L., Cardin, D. B., Shahda, S., Lenz, H., Dotan, E., O’Neil, B. H., Kapoun, A. M., Stagg, R., Berlin, J. D., Messersmith, W. A., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00824-1 · Cited by 112
Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients
Chung, V. M., Sun, V. C.-Y., Ruel, N. H., Smith, T. J., & FERRELL, B. R. (2021) · Journal of Palliative Medicine · doi:10.1089/jpm.2021.0187 · Cited by 112
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma
Jesus‐Acosta, A. D., Laheru, D. A., Maitra, A., Arcaroli, J. J., Rudek, M. A., Dasari, A. N., Blatchford, P. J., Quackenbush, K. S., & Messersmith, W. A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0083-8 · Cited by 111
Self-citation
Patient-Derived Xenograft Models for Pancreatic Adenocarcinoma Demonstrate Retention of Tumor Morphology through Incorporation of Murine Stromal Elements
Delitto, D., Pham, K., Vlada, A. C., Sarosi, G. A., Thomas, R. M., Behrns, K. E., Liu, C., Hughes, S. J., Wallet, S. M., & Trevino, J. G. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.01.016 · Cited by 111
The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
Houg, D. S., & Bijlsma, M. F. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0842-9 · Cited by 114
Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model
Narayanan, J. S. S., Ray, P., Hayashi, T., Whisenant, T. C., Vicente, D. A., Carson, D. A., Miller, A. M., Schoenberger, S. P., & White, R. R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0101 · Cited by 111
Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer
Iwai, N., Okuda, T., Sakagami, J., Harada, T., Ohara, T., Taniguchi, M., Sakai, H., Oka, K., Hara, T., Tsuji, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75745-8 · Cited by 111
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)
Yamaguchi, J., Yokoyama, Y., Fujii, T., Yamada, S., Takami, H., Kawashima, H., Ohno, E., Ishikawa, T., Maeda, O., Ogawa, H., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005430 · Cited by 111
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
Dhir, M., Zenati, M. S., Hamad, A. B., Singhi, A. D., Bahary, N., Hogg, M. E., Zeh, H. J., & Zureikat, A. H. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6512-8 · Cited by 110
Self-citation
Nomogram Predicts Risk and Prognostic Factors for Bone Metastasis of Pancreatic Cancer: A Population-Based Analysis
Zhang, W., Ji, L., Wang, X., Zhu, S., Luo, J., Zhang, Y., Yu, T., Feng, F., Kang, Y., & Bi, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.752176 · Cited by 110
Collision of herbal medicine and nanotechnology: a bibliometric analysis of herbal nanoparticles from 2004 to 2023
Ai, S., Li, Y., Zheng, H., Zhang, M., Tao, J., Liu, W., Peng, L., Wang, Z., & Wang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02426-3 · Cited by 110
Value of Intraoperative Neck Margin Analysis During Whipple for Pancreatic Adenocarcinoma
Kooby, D. A., Lad, N. L., Squires, M. H., Maithel, S. K., Sarmiento, J. M., Staley, C. A., Adsay, V. N., El‐Rayes, B. F., Weber, S. M., Winslow, E. R., et al. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000890 · Cited by 110
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T., Walgren, R. A., & Stemmer, S. M. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12331 · Cited by 109
Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancer
Martin, H. L., Ohara, K., Kiberu, A. D., van Hagen, T., Davidson, A., & Khattak, M. A. (2014) · Internal Medicine Journal · doi:10.1111/imj.12453 · Cited by 109
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
Chiorean, E. G., Hoff, D. D. V., Reni, M., Arena, F. P., Infante, J. R., Bathini, V., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw006 · Cited by 109
Self-citation
Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression
Wilson, J. S., Pirola, R. C., & Apte, M. V. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00052 · Cited by 108
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
Şahin, İ. H., Askan, G., Hu, Z., & O'Reilly, E. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx503 · Cited by 108
Sequential delivery of nanoformulated α-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer
Feng, J., Xu, M., Wang, J., Zhou, S., Liu, Y., Liu, S., Huang, Y., Chen, Y., Liang, C., Song, Q., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119907 · Cited by 108
The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol
Moyer, M. T., Sharzehi, S., Mathew, A., Levenick, J. M., Headlee, B. D., Blandford, J. T., Heisey, H. D., Birkholz, J. H., Ancrile, B. B., Maranki, J. L., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.009 · Cited by 108
Targeted polyethylene glycol gold nanoparticles for the treatment of pancreatic cancer: from synthesis to proof-of-concept in vitro studies
Spadavecchia, J., Movia, D., Moore, C., Maguire, C. M., Moustaoui, H., Casale, S., Volkov, Y., & Prina‐Mello, A. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s97476 · Cited by 108
ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
Adamska, A., & Falasca, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3222 · Cited by 107
Tumor-associated macrophages in pancreatic ductal adenocarcinoma: therapeutic opportunities and clinical challenges
Poh, A. R., & Ernst, M. (2021) · Cancers · doi:10.3390/cancers13122860 · Cited by 106
Quality of Life of Patients With Advanced Pancreatic Cancer During Treatment With Mistletoe
Tröger, W., Galun, D. A., Reif, M., Schumann, A., Stanković, N., & Milićević, M. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0493 · Cited by 106
Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment
Tanaka, H. Y., & Kano, M. R. (2018) · Cancer Science · doi:10.1111/cas.13630 · Cited by 106
International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer
Takaori, K., Bassi, C., Biankin, A. V., Brunner, T. B., Cataldo, I., Campbell, F., Cunningham, D., Falconi, M., Frampton, A. E., Furuse, J., et al. (2015) · Pancreatology · doi:10.1016/j.pan.2015.10.013 · Cited by 105
Systemic treatment of pancreatic cancer revisited
Ducreux, M. P., Seufferlein, T. T. W., Laethem, J. V., Laurent‐Puig, P., Smolenschi, C., Malka, D., Boige, V., Hollebecque, A., & Conroy, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.12.003 · Cited by 105
Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program
Pishvaian, M. J., Blais, E. M., Brody, J. R., Rahib, L., Lyons, E. E., Arbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sohal, D. P. S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00115 · Cited by 105
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
Samanta, K., Setua, S., Kumari, S., Jaggi, M., Yallapu, M. M., & Chauhan, S. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110574 · Cited by 105
Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer
Hakim, N., Patel, R., Devoe, C., & Saif, M. W. (2019) · Pancreas - Open Journal · doi:10.17140/poj-3-e010 · Cited by 105
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Liu, L., Huang, X., Shi, F., Song, J., Guo, C., Yang, J., Liang, T., & Bai, X. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02273-w · Cited by 105
The Role of Immunotherapy in Pancreatic Cancer
Mukherji, R., Debnath, D., Hartley, M. L., & Noel, M. S. (2022) · Current Oncology · doi:10.3390/curroncol29100541 · Cited by 106
Pancreatic cancer subtypes: a roadmap for precision medicine
Torres, C., & Grippo, P. J. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1453168 · Cited by 104
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Van Cutsem, E., Hidalgo, M., Canon, J., Macarulla, T., Bazin, I., Poddubskaya, E., Manojlovic, N., Radenkovic, D., Verslype, C., Raymond, E., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31603 · Cited by 104
Self-citation
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression
Duan, W., Chen, K., Jiang, Z., Chen, X., Sun, L., Li, J., Lei, J., Xu, Q., Ma, J., Li, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.019 · Cited by 104
Scoparone as a therapeutic drug in liver diseases: Pharmacology, pharmacokinetics and molecular mechanisms of action
Hui, Y., Wang, X., Yu, Z., Fan, X., Cui, B., Zhao, T., Mao, L., Feng, H., Lin, L., Yu, Q., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105170 · Cited by 104
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Hewitt, D. B., Nissen, N., Hatoum, H., Musher, B., Seng, J., Coveler, A. L., Al-Rajabi, R., Yeo, C. J., Leiby, B., Banks, J., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004669 · Cited by 104
Medical gas plasma technology: Roadmap on cancer treatment and immunotherapy
Bekeschus, S. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102798 · Cited by 104
Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma
Gifford, J. B., Huang, W., Zeleniak, A. E., Hindoyan, A. A., Wu, H., Donahue, T. R., & Hill, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0774 · Cited by 104
Pancreatic cancer stem cells: New insight into a stubborn disease
Zhan, H., Xu, J., Wu, D., Zhang, T., & Hu, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.004 · Cited by 103
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma
O'Reilly, E. M., Lee, J. W., Lowery, M. A., Capanu, M., Stadler, Z. K., Moore, M. J., Dhani, N. C., Kindler, H. L., Estrella, H., Maynard, H., et al. (2018) · Cancer · doi:10.1002/cncr.31218 · Cited by 103
Self-citation
Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer
DeWitt, J. M., Sandrasegaran, K., O’Neil, B. H., House, M. G., Zyromski, N. J., Sehdev, A., Perkins, S. M., Flynn, J., McCranor, L., & Shahda, S. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2018.09.007 · Cited by 103
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2 ) Mutation
Du, C., Qi, Y., Zhang, Y., Wang, Y., Zhao, X., Min, H., Han, X., Lang, J., Qin, H., Shi, Q., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b01573 · Cited by 103
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
García‐Carbonero, R., Bazán‐Peregrino, M., Gil-Martín, M., Álvarez-Gallego, R., Macarulla, T. M., Martínez, M. C. R., Verdaguer, H., Guillén‐Ponce, C., Farrera-Sal, M., Moreno, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003255 · Cited by 103
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort
Taı̈eb, J., Sayah, L., Heinrich, K., Kunzmann, V., Boilève, A., Cirkel, G. A., Lonardi, S., Chibaudel, B., Turpin, A., Beller, T., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.04.012 · Cited by 103
Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer
Boilève, A., Cartry, J., Goudarzi, N., Bedja, S., Mathieu, J. R. R., Bani, M. A., Nicolle, R., Mouawia, A., Bouyakoub, R., Nicotra, C., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.032 · Cited by 103
Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment
Polireddy, K., & Chen, Q. (2016) · Journal of Cancer · doi:10.7150/jca.14922 · Cited by 103
The acinar regulator Gata6 suppresses Kras G12V -driven pancreatic tumorigenesis in mice
Martinelli, P., Madriles, F., Cañamero, M., Pau, E. C. D. S., del Pozo, N., Guerra, C. E., & Real, F. X. (2015) · Gut · doi:10.1136/gutjnl-2014-308042 · Cited by 102
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
Bendell, J. C., O'Reilly, E. M., Middleton, M. R., Chau, I., Höchster, H. S., Fielding, A., Burke, W., & Burris, H. A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu581 · Cited by 102
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
Chandana, S. R., Babiker, H. M., & Mahadevan, D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1557145 · Cited by 102
Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies
van Veldhuisen, E., van den Oord, C., Brada, L. J. H., Walma, M. S., Vogel, J. A., Wilmink, J. W., Chiaro, M. D., van Lienden, K. P., Meijerink, M. R., van Tienhoven, G., et al. (2019) · Cancers · doi:10.3390/cancers11070976 · Cited by 102
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Xie, C., Duffy, A. G., Brar, G. S., Fioravanti, S., Mabry‐Hrones, D., Walker, M., Bonilla, C. M., Wood, B. J., Citrin, D. E., Ramirez, E. M. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3624 · Cited by 102
PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer
Kim, D. K., Jeong, J., Lee, D. S., Hyeon, D. Y., Park, G. W., Jeon, S., Lee, K. B., Jang, J., Hwang, D., Kim, H. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33991-6 · Cited by 102
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. G., Chiaro, M. D., Tempero, M. A., Malafa, M. P., Benson, A. B., Cardin, D. B., Christensen, J. A., Chung, V. M., Czito, B. G., Dillhoff, M. E., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0034 · Cited by 102
Self-citation
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities
Qin, Q., Yu, R., Eriksson, J., Tsai, H., & Zhu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216859 · Cited by 102
SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma
Dardare, J., Witz, A., Merlin, J.-L., Gilson, P., & Harlé, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103534 · Cited by 101
Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer
Farren, M. R., Mace, T. A., Geyer, S. M., Mikhail, S., Wu, C. S.-Y., Ciombor, K. K., Tahiri, S., Ahn, D. H., Noonan, A. M., Villalona-Calero, M. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1732 · Cited by 101
Pancreatic cancer: Current research and future directions
Falasca, M., Kim, M., & Casari, I. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.01.001 · Cited by 101
Neoadjuvant Treatment for Pancreatic Cancer
Raufi, A. G., Manji, G. A., Chabot, J. A., & Bates, S. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.12.002 · Cited by 101
A Phase III Open-Label Trial to Evaluate Efficacy and Safety of CPI-613 Plus Modified FOLFIRINOX (MFFX) versus FOLFIRINOX (FFX) in Patients with Metastatic Adenocarcinoma of the Pancreas
Philip, P. A., Buyse, M. E., Alistar, A. T., Lima, C. M. S. R., Luther, S., Pardee, T. S., & Cutsem, E. V. (2019) · Future Oncology · doi:10.2217/fon-2019-0209 · Cited by 101
Prognostic and predictive factors in pancreatic cancer
Dell’Aquila, E., Fulgenzi, C. A. M., Minelli, A., Citarella, F., Stellato, M., Pantano, F., Russano, M., Cursano, M. C., Napolitano, A., Zeppola, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27518 · Cited by 101

Authors: Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M., Goldstein, D., Van Cutsem, E., Wei, X., Iglesias, J., & Renschler, M. F.
Affiliations: University of Washington (US)
Tennessee Oncology (US)
Princess Margaret Cancer Centre (CA)
Russian Cancer Research Center NN Blokhin (RU)
Translational Genomics Research Institute (US)
Georgia Cancer Specialists (US)
Sidney Kimmel Comprehensive Cancer Center (US)
University of Pittsburgh Medical Center (US)
Universitat Autònoma de Barcelona (ES)
Prince of Wales Hospital (AU)
Celgene (United States) (US)
Bionomics (Australia) (AU)
ORCID: Arena, Francis P.
Chiorean, E. Gabriela
Moore, Malcolm
Tjulandin, Sergei A.
Ma, Wen Wee
Saleh, Mansoor N.
Harris, Marion
Reni, Michele
Laheru, Daniel
Bahary, Nathan
Tabernero, Josep
Hidalgo, Manuel
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-10-31
Volume: 369
Issue: 18
Pages: 1691-1703
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1304369
PMC: PMC4631139
OpenAlex: W2165480504
Cited by: 6,712
References: 23
Citations by year: 2026: 403 · 2025: 491 · 2024: 537 · 2023: 607 · 2022: 614 · 2021: 695 · 2020: 631 · 2019: 531 · 2018: 548 · 2017: 512 · 2016: 423 · 2015: 424 · 2014: 271 · 2013: 15
FWCI: 200.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P30CA006973)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords: pancreatic cancer, metastatic pancreatic cancer, nab-paclitaxel, gemcitabine, combination chemotherapy, gemcitabine monotherapy, overall survival, progression-free survival, overall response rate, treatment safety, adverse events, chemotherapy schedule, Karnofsky performance status
MeSH terms: Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Albumins, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Female, Humans, Male, Middle Aged, Nervous System Diseases, Neutropenia, Pancreatic Neoplasms, Paclitaxel, Disease-Free Survival, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks